Context Therapeutics Inc. (NASDAQ:CNTX) Insider Alex C. Levit Purchases 20,000 Shares

Context Therapeutics Inc. (NASDAQ:CNTX) insider Alex C. Levit acquired 20,000 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were bought at an average cost of $0.58 per share, for a total transaction of $11,600.00. Following the acquisition, the insider now owns 29,000 shares in the company, valued at approximately $16,820. The trade was a 222.22% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $0.67 on Wednesday. The firm has a 50-day moving average of $0.75 and a 200-day moving average of $0.92. The stock has a market cap of $59.97 million, a PE ratio of -0.73 and a beta of 1.86. Context Therapeutics Inc. has a 52-week low of $0.49 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Equities research analysts predict that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CNTX. Jane Street Group LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth approximately $29,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth approximately $31,000. Millennium Management LLC raised its position in Context Therapeutics by 24.2% in the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after buying an additional 34,835 shares during the last quarter. Shay Capital LLC purchased a new stake in Context Therapeutics in the 4th quarter valued at $52,000. Finally, Geode Capital Management LLC raised its position in Context Therapeutics by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after buying an additional 52,830 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on CNTX. William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Thursday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Context Therapeutics has an average rating of “Buy” and an average target price of $6.00.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.